The new EU AMR Action plan

Arjon van Hengel, PhDEuropean Commission

DG Research and InnovationHealth Directorate

'Fighting infectious diseases and advancing public health'

The 2011-2016 EU action plan

• had a clear EU added value, was a symbol of politicalcommitment, and stimulated actions within Member States

• contributed to a global acceptance of the need for a OneHealth approach

• led to the development of the upcoming veterinarymedicinal products and medicated feed regulation

• led to unprecedented public-private collaborative researchand development to bring new antibiotics to patients ->IMI's New Drugs for Bad Bugs

• reinforced and co-ordinated research efforts e.g. viaestablishing the Joint Programming Initiative on AMR

• boosted international cooperation (G7, G20, UN, WHO,TATFAR)

The Action plan against the rising threats fromantimicrobial resistance launched on 17 November2011

#EUAMRaction

ONE HEALTH

MAKING THE EU A BESTPRACTICE REGION ON AMR

• Better evidence andawareness

• Better coordination andimplementation of EU rules

• Better prevention andcontrol

• Better addressing the role ofthe environment

• A stronger partnershipagainst AMR and betteravailability of antimicrobials

MAKING THE EU A BESTPRACTICE REGION ON AMR

• Better evidence andawareness

• Better coordination andimplementation of EU rules

• Better prevention andcontrol

• Better addressing the role ofthe environment

• A stronger partnershipagainst AMR and betteravailability of antimicrobials

BOOSTING RESEARCH,DEVELOPMENT AND

INNOVATION ON AMR

• New economic models &incentives

• New antimicrobials, rapiddiagnostic tests, vaccines &alternative therapies

BOOSTING RESEARCH,DEVELOPMENT AND

INNOVATION ON AMR

• New economic models &incentives

• New antimicrobials, rapiddiagnostic tests, vaccines &alternative therapies

SHAPING THE GLOBALAGENDA ON AMR

• Stronger EU global presence,partnering

• Stronger bilateralpartnership for strongercooperation

• Cooperating with developingcountries

• Developing a global researchagenda

SHAPING THE GLOBALAGENDA ON AMR

• Stronger EU global presence,partnering

• Stronger bilateralpartnership for strongercooperation

• Cooperating with developingcountries

• Developing a global researchagenda

1. Better evidence and awareness of the challenges of AMR• Strengthen One Health surveillance and reporting of AMR and

antimicrobial use• Benefit from the best evidence-based analysis and data• Increase awareness and understanding

2. Better coordination and implementation of EU rules to tackle AMR• Improve the coordination of Member States’ One Health

responses to AMR• Better implementation of EU rules

3. Better prevention and control of AMR• Strengthen infection prevention and control measures• Promote the prudent use of antimicrobials

4. Better addressing the role of the environment5. A stronger partnership against AMR and better availability of

antimicrobials

1. Better evidence and awareness of the challenges of AMR• Strengthen One Health surveillance and reporting of AMR and

antimicrobial use• Benefit from the best evidence-based analysis and data• Increase awareness and understanding

2. Better coordination and implementation of EU rules to tackle AMR• Improve the coordination of Member States’ One Health

responses to AMR• Better implementation of EU rules

3. Better prevention and control of AMR• Strengthen infection prevention and control measures• Promote the prudent use of antimicrobials

4. Better addressing the role of the environment5. A stronger partnership against AMR and better availability of

antimicrobials

MAKING THE EU A BEST PRACTICE REGION ON AMRMAKING THE EU A BEST PRACTICE REGION ON AMR

Research Development and Innovationat the centre of the new Action planResearch Development and Innovationat the centre of the new Action plan

For making the EU a best practise region (pillar 1) and toshape the global agenda (pillar 3) we need to invest in novelknowledge, tools and solutions for which we rely on research

We will make use of different funding instruments undercurrent and future framework programmes for research andinnovation

We should make use of our brightest minds as well as use allthe latest developments in technology, data handling and IT.

*Special attention to WHO's priority list, TB, HIV, malaria and neglectedinfectious diseases

For making the EU a best practise region (pillar 1) and toshape the global agenda (pillar 3) we need to invest in novelknowledge, tools and solutions for which we rely on research

We will make use of different funding instruments undercurrent and future framework programmes for research andinnovation

We should make use of our brightest minds as well as use allthe latest developments in technology, data handling and IT.

*Special attention to WHO's priority list, TB, HIV, malaria and neglectedinfectious diseases

Boosting research, development andinnovationBoosting research, development andinnovation

1. Improve knowledge on detection, effective infection control and surveillanceThe Commission will:

support development and assessment of interventions to prevent the developmentand spread of AMR

support research into the understanding of epidemiology and transmission of AMR support research into early detection of resistant pathogens support research into new eHealth solutions to improve prescription practices, self-

management, care solutions and awareness2. Develop new therapeutics and alternativesThe Commission will:

support development of new antimicrobials and alternatives, repurposing of oldantibiotics, and the development of combination therapies

support SMEs in their R&D efforts facilitate sharing of AMR research data to guide discovery and development support the establishment of a European-wide sustainable clinical research network support the use of digital technologies to develop therapeutics and alternatives

Boosting research, development andinnovationBoosting research, development andinnovation

3. Develop new preventive vaccinesThe Commission will:

continue to support development of new effective preventive vaccines for humansand animals

support increasing the knowledge base concerning barriers influencing the wideruse of vaccination in medical and veterinary practice

4. Develop novel diagnosticsThe Commission will:

support development of new diagnostic tools, in particular on-site tests to guidepractitioners regarding the use of antimicrobials

support the use of IT solutions in diagnostic tools encourage the uptake of diagnostics in medical and veterinary practice (e.g.

through innovation procurement)

Boosting research, development andinnovationBoosting research, development andinnovation

3. Develop new economic models and incentivesThe Commission will:

increase the evidence base for understanding societal costs and benefits ofstrategies to fight AMR

support research into new economic models and incentives to boost development analyse regulatory tools and incentives (e.g. orphan and paediatric legislation) encourage Member States to explore results and recommendations of EU research

projects on new economic business models develop new or improved HTA approaches and foster consensus building

4. Close knowledge gaps on AMR in the environment and on preventingtransmissionThe Commission will:

support research into knowledge gaps on release and spread in the environment explore risk assessment methodologies to evaluate risks to human/animal health support research to develop tools to monitor AMR in the environment support technologies that degrade antimicrobials / reduce environmental spread

1. Stronger EU global presence• Contribute towards WHO, OIE, FAO, and Codex Alimentarius on

development of international frameworks and standards/norms/ guidelines/methodologies

• Sustain political attention and commitment to AMR action,including in the United Nations, G7 and the G20

2. Stronger bilateral partnerships for stronger cooperation• Advocate EU standards and measures for tackling AMR in trade

agreements• Engage with major global players and strategic countries

(Brazil, China, India)3. Cooperating with developing countries

• Assist development of AMR strategies in food safety and animalhealth areas via regional training workshops (BTSF World)

4. Developing a global research agenda• improve global coordination of research by promoting dialogue

and collaboration between international research initiatives

1. Stronger EU global presence• Contribute towards WHO, OIE, FAO, and Codex Alimentarius on

development of international frameworks and standards/norms/ guidelines/methodologies

• Sustain political attention and commitment to AMR action,including in the United Nations, G7 and the G20

2. Stronger bilateral partnerships for stronger cooperation• Advocate EU standards and measures for tackling AMR in trade

agreements• Engage with major global players and strategic countries

(Brazil, China, India)3. Cooperating with developing countries

• Assist development of AMR strategies in food safety and animalhealth areas via regional training workshops (BTSF World)

4. Developing a global research agenda• improve global coordination of research by promoting dialogue

and collaboration between international research initiatives

Shaping the global agendaShaping the global agenda

• Improve global coordination of research activities by promotingdialogue and collaboration between international researchinitiatives

• as requested by G7 and G20 Health Ministers

• Support the establishment of a virtual research institute underJPIAMR

• Joint programming initiative on AMR, a public–public partnership:19European countries, Israel, Argentina, Canada, Japan, Egypt, South-Africa and India

• Improve global coordination of research activities by promotingdialogue and collaboration between international researchinitiatives

• as requested by G7 and G20 Health Ministers

• Support the establishment of a virtual research institute underJPIAMR

• Joint programming initiative on AMR, a public–public partnership:19European countries, Israel, Argentina, Canada, Japan, Egypt, South-Africa and India

Developing a global research agendaDeveloping a global research agenda

The Commission will:

• Continue collaborative research with sub-Saharan Africa in thecontext of EDCTP, in particular in relation to TB, HIV, malaria andNID

• European and Developing Countries Clinical Trials Partnership (EDCTP2)a partnership between 14 European and 14 African countries

• Foster international research collaboration on AMR in the animalhealth sector in the STAR-IDAZ International Research Consortium

• Global Strategic Alliances for the Coordination of Research on the MajorInfectious Diseases of Animals and zoonoses

• Continue collaborative research with sub-Saharan Africa in thecontext of EDCTP, in particular in relation to TB, HIV, malaria andNID

• European and Developing Countries Clinical Trials Partnership (EDCTP2)a partnership between 14 European and 14 African countries

• Foster international research collaboration on AMR in the animalhealth sector in the STAR-IDAZ International Research Consortium

• Global Strategic Alliances for the Coordination of Research on the MajorInfectious Diseases of Animals and zoonoses

Developing a global research agendaDeveloping a global research agenda

The Commission will:

CollaborativeprojectsPublic-private

partnership withbig pharma

Public-publicpartnerships withEU Member States

& beyond

Blue sky researchGrants for smallbusinesses

Loans for small andbig R&I companies

Knowledge triangle:Higher education,

business, R&I

The fight against AMR:one challenge, many instruments

GTBVPGTBVP

Thank you for yourattention